Skip to main content
SpringerLink
Log in

Erythrocytes as Drug Carriers in Medicine

  • Book
  • © 1997

Overview

Editors:
  1. Ulrich Sprandel

    1. Kreiskrankenhaus, Marktoberdorf, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. James L. Way

    1. Texas A&M University, College Station, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (19 chapters)

  1. Front Matter

    Pages i-viii
    Download chapter PDF

  2. A Model for the Assessment of Human Recombinant Interleukin 2 (RIL2) Coated Erythrocytes as a Delivery System for Immunotherapy

    • R. B. Moyes, J. R. DeLoach
    Pages 1-11

  3. Human Recombinant Interleukin 2 Binds to Mouse Red Blood Cells via the Erythropoietin Receptor

    • Rita B. Moyes, John R. DeLoach
    Pages 13-23

  4. In Vivo Survival of Human Energy-Replete Carrier Erythrocytes

    • Murray D. Bain, Bridget E. Bax, Peter J. Talbot, E. John Parker-Williams, Ronald A. Chalmers
    Pages 25-30

  5. The Entrapment of Polyethylene Glycol-Conjugated Adenosine Deaminase (Pegademase) and Native Adenosine Deaminase in Human Carrier Erythrocytes

    • Bridget E. Bax, Lynette D. Fairbanks, Murray D. Bain, H. Anne Simmonds, Ronald A. Chalmers
    Pages 31-34

  6. Use of Erythrocytes as a New Route of Administration of Fibrinolytic Agents

    • Benedicte Delahousse, Roger Kravtzoff, Claude Ropars
    Pages 35-42

  7. Synthesis, Characterization and Erythrocyte Encapsulation of an Azidothymidine Homodinucleotide

    • Marco Giovine, Sonia Scarfi, Anna Gasparini, Enrico Millo, Gianluca Damonte, Antonio De Flora et al.
    Pages 43-50

  8. Erythrocyte-Based Targeted Release to Macrophages of an Azidothymidine Homodinucleotide Prevents Retroviral Infection

    • Umberto Benatti, Marco Giovine, Gianluca Damonte, Antonio De Flora, Rosamund Williams, Sandra Gessani et al.
    Pages 51-57

  9. The Entrapment of Mannose-Terminated Glucocerebrosidase (Alglucerase) in Human Carrier Erythrocytes

    • Bridget E. Bax, Murray D. Bain, Chandra P. Ward, Anthony H. Fensom, Ronald A. Chalmers
    Pages 59-62

  10. Macrophage Protection by Nucleoside and Nucleotide Analogue Administration

    • L. Rossi, A. Casabianca, A. Fraternale, G. F. Schiavano, G. Brandi, A. Antonelli et al.
    Pages 63-71

  11. Inhibition of Murine AIDS by Combination of AZT and DDCTP-Loaded Erythrocytes

    • A. Fraternale, A. Casabianca, L. Rossi, L. Chiarantini, G. Brandi, G. Aluigi et al.
    Pages 73-79

  12. Red Blood Cells as a Glucocorticoids Delivery System

    • M. D’Ascenzo, A. Antonelli, L. Chiarantini, U. Mancini, M. Magnani
    Pages 81-88

  13. Organophosphorus Antagonism by Resealed Erythrocytes Containing Recombinant Paraoxonase

    • J. L. Way, L. Pei, I. Petrikovics, D. McGuinn, C. Tamulinas, Q. Z. Hu et al.
    Pages 89-92

  14. Biotinylation of Erythrocytes Prepares to Allow Circulation-Stable Immunoerythrocytes Capable of Recognizing the Antigen

    • Juan C. Murciano, Vladimir R. Muzykantov, Angel Herráez
    Pages 93-99

  15. Biochemical Properties of Alcohol Dehydrogenase and Glutamate Dehydrogenase Encapsulated into Human Erythrocytes by a Hypotonic-Dialysis Procedure

    • Silvia Sanz, Carmen Lizano, Marina I. Garín, José Luque, Montserrat Pinilla
    Pages 101-108

  16. Influence of Chemical Modification on “In Vivo” and “In Vitro” Mouse Carrier Erythrocyte Survival and Recognition

    • J. A. Jordán, F. J. Alvarez, J. C. Murciano, A. Lotero, A. Herráez, M. C. Tejedor et al.
    Pages 109-118

  17. Rat Carrier Erythrocytes Circulate and Arrive to Organs

    • F. J. Alvarez, J. A. Jordán, J. C. Murciano, J. Luque, A. Herráez, J. C. Díez et al.
    Pages 119-127

  18. Encapsulation of Alcohol Dehydrogenase and Acetaldehyde Dehydrogenase into Human Erythrocytes by an Electroporation Procedure

    • Carmen Lizano, Silvia Sanz, Pilar Sancho, José Luque, Montserrat Pinilla
    Pages 129-135

  19. Pharmacokinetics of Doxorubicin in Patients with Lymphoproliferative Disorders after Infusion of Doxorubicin-Loaded Erythrocytes

    • Fazoil I. Ataullakhanov, Valentin G. Isaev, Alina V. Kohno, Elena V. Kulikova, Elena N. Parovichnikova, Valery G. Savchenko et al.
    Pages 137-142

  20. Binding of Daunorubicin and Doxorubicin to Erythrocytes Treated with Glutaraldehyde

    • Fazoil I. Ataullakhanov, Elena V. Kulikova, Victor M. Vitvitsky
    Pages 143-148
Back to top

Keywords

About this book

The sixth meeting on the use of resealed annealed red blood cells was held in Irsee, Germany by the International Society for the Use of Resealed Erythrocytes (ISURE) on July 25-28, 1996. Although earlier meetings focused on the technology toward develop­ ment of methods and standardization for efficient, consistent encapsulation, most of the present studies now are directed toward the application use of these carrier blood cells. Basic studies now have been directed toward exploration of commercial applications. In­ deed, clinical trials were initiated to evaluate the dose-response curves employing L­ asparagenase in human patients. Also, studies have shown the use of thrombolytic agent in erythrocyte carriers with the use of human red blood cells to provide a new conceptual ap­ proach in thrombolytic therapy to prevent thrombosis in individuals with higher risk fac­ tors. For example, with the use of carrier red blood cells, the thrombolytic agents will have a greater potential of acting on clot formation without systemic activation and thus lower the risk of hemorrhage, which is always prevalent in the thrombolytic therapy.

Editors and Affiliations

  • Kreiskrankenhaus, Marktoberdorf, Germany

    Ulrich Sprandel

  • Texas A&M University, College Station, USA

    James L. Way

Bibliographic Information

  • Book Title: Erythrocytes as Drug Carriers in Medicine

  • Editors: Ulrich Sprandel, James L. Way

  • DOI: https://doi.org/10.1007/978-1-4899-0044-9

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 1997

  • Hardcover ISBN: 978-0-306-45599-5Published: 31 May 1997

  • Softcover ISBN: 978-1-4899-0046-3Published: 07 June 2013

  • eBook ISBN: 978-1-4899-0044-9Published: 29 June 2013

  • Edition Number: 1

  • Number of Pages: VIII, 150

  • Topics: Hematology

Publish with us

Policies and ethics

Back to top

Search

Navigation